Special Issue "Antituberculosis Drugs"

Guest Editor
Dr. Marcelo J. Nieto
Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026-2000, USA
E-Mail: mnieto@siue.edu
Interests: drug design; parallel synthesis; antibacterials; antimalarials; antimycobacterials; natural products; antivirals

Dear Colleagues,

Tuberculosis (TB), a disease cause by Mycobacterium tuberculosis (Mt), is one of the deadliest infectious diseases. Each year almost 2 million people die worldwide according to estimates from the World Health Organization (WHO). The treatment for tuberculosis is more than 30 years old and includes a multidrug approach during a long period of time (6-9 months). There are several resistant strains of Mt including multidrug (MDR) strains resistant to more than one first line drugs and extremely resistant strains (XDR), resistant to first and second line drugs. These strains have made Mt and TB very difficult to treat and eradicate. This special issue will focus on the biology of Mt, resistance, new targets, drug discovery and development, and clinical trials.

Dr. Marcelo J. Nieto
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• Mycobacterium tuberculosis
• TB resistance
• drug discovery
• mode of action
• clinical trials
• drug development
• opportunistic infections